I agree. I wouldn't sell at these prices even if we didn't have NNZ-2256!
Daybue guidance (70m AUD) on a 40 forward PE = 2.8B AUD. We also have 250m cash on top of this. Zero value assigned to NNZ-2256
This 40 forward PE is very reasonable because:
- Peak sales won't be achieved in the first full year, so there will be growth in the coming years (North America)
- Additional geographies will add more sales, even if the pricing isn't as strong as North America (Europe and Japan, EMA)
- Milestone payments aren't included in my calculations, but they go straight to earnings. These milestones are reasonable and many of them can be hit within a reasonable time frame. An additional 77m~ is projected to be comfortably hit based on the guidance already provided.
- PRV isn't included in these calculations.
- We have very low expenses compared to peers and, our expenses spent on R&D are partially a tax deduction.
- Forums
- ASX - By Stock
- NEU
- Ann: 2023 Annual Report to shareholders
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.80%
!
$12.54

Ann: 2023 Annual Report to shareholders, page-73
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B |
Open | High | Low | Value | Volume |
$12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1215 | $12.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.54 | 804 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 400 | 12.480 |
1 | 796 | 12.300 |
1 | 400 | 12.240 |
1 | 3000 | 12.230 |
1 | 761 | 12.210 |
Price($) | Vol. | No. |
---|---|---|
12.600 | 1020 | 1 |
12.710 | 628 | 2 |
12.720 | 1982 | 1 |
12.820 | 3050 | 1 |
12.900 | 5012 | 1 |
Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |